I would think that $150+/share is a possibility. That all depends on what timeline you are projecting, and how widely adapted a Multikine cancer pre-treatment becomes.
If a Multikine pre-treatment demonstrates an improvement in outcome (not being dead) of 10% or more - I suspect it could be come very widely used - especially if it lowers the costs of long-term treatment and recovery for the health care system and insurance companies.
I don't think we see it hit $150 though until at least 1 or 2 things happen first. 1) We get into a partnership of some kind with an existing big-pharma company that markets 'our' drug with something they already have that helps grease the revenue skids, or 2) Sales just plain take off.
IF the results indicate that there is a 10% or greater improvement in patient outcome as part of the Phase III testing, then I think we fairly quickly see 2x or so over what we have now. I think a lot of the potential bump short-term bump is already built into the current share price.
News 
Market Data 
Discover 
